Core Viewpoint - Zimmer Biomet Holdings, Inc. (ZBH) is set to report its fourth-quarter 2025 results on February 10, with expectations of revenue growth and earnings per share (EPS) increase compared to the previous year [1][9]. Group 1: Financial Estimates - The Zacks Consensus Estimate for ZBH's revenues is $2.20 billion, reflecting an 8.9% increase from the same quarter last year [2]. - The consensus estimate for earnings is $2.38 per share, indicating a 3% rise from the year-ago figure [2]. - The bottom-line estimate has remained unchanged over the past 30 days [2]. Group 2: Business Segment Performance - The Hips business is expected to grow due to the company's comprehensive solutions, including the new Z1 triple-taper hip system and the automated HAMMR surgical impactor [3][4]. - The total Hips business is projected to report a 10.5% year-over-year growth [5]. - The Knees business is likely to benefit from the increasing adoption of the Persona OsseoTi cementless total knee system, with an expected 7.5% year-over-year growth [6]. - The S.E.T business is anticipated to continue its growth trend, with expectations of mid-single-digit growth for the seventh consecutive quarter [7]. - New product launches in the foot and ankle trauma portfolio, such as the Gorilla Pilon Fusion Plating system, may positively impact fourth-quarter performance [8]. Group 3: Recent Developments - Zimmer Biomet received PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System, which may enhance top-line performance [5]. - The acquisition of Paragon 28, Inc. and the CE Mark certification for the RibFix Advantage Fixation System are expected to contribute positively to the company's performance [10]. - The company completed the acquisition of Monogram Technologies Inc., an AI-driven orthopedic robotics firm, which may also have a favorable impact on fourth-quarter results [12]. Group 4: Growth Projections - The Technology & Data, Bone Cement, and Surgical business is estimated to report a 6.5% year-over-year growth for the quarter [13]. - The total S.E.T. business is projected to achieve a 13% year-over-year growth [10].

Core Insights - Zimmer Biomet Holdings, Inc. (ZBH) received approval from the Pharmaceutical and Medical Devices Agency (PMDA) in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology, which inhibits bacterial adhesion on the implant surface [1][10] - The approval enhances ZBH's infection management portfolio, which includes prevention, detection, primary, and revision products [1][10] Product Significance - The iTaperloc and iG7 systems combine the clinical heritage of the Taperloc Complete Hip System with the performance of the G7 Acetabular System, enhanced by Iodine Technology [2] - Implant-associated bacterial infection, or Periprosthetic Joint Infection (PJI), is a significant complication in total joint arthroplasty (TJA), occurring in an estimated 1-2% of primary TJA procedures [3] - The mortality rate associated with PJI is comparable to that of breast cancer, highlighting the critical need for effective solutions [4] Iodine Technology - Iodine is a biocompatible nutrient that does not contribute to antibiotic resistance and is used in medicine as an antiseptic [5] - The application of Iodine Technology during manufacturing inhibits biofilm formation on the implant surface [5] Market Outlook - The global orthopedic implants market is projected to reach $32.47 billion by 2030, growing at a CAGR of 3.78% from 2025 to 2030, driven by increasing prevalence of musculoskeletal disorders [6] Strategic Developments - Zimmer Biomet has agreed to acquire Monogram Technologies Inc., an orthopedic robotics company, for an upfront payment of $4.04 per share, totaling approximately $177 million in equity value [7] - The acquisition aims to enhance ZBH's ROSA Robotics platform with new capabilities from Monogram's semi and fully autonomous robotic technologies, expected to be completed by the end of 2025 [8]